Putting a Price on Life: Is the Answer Outside Pharma?
To cure the previously incurable we must take two giant steps: the first towards better understanding the science behind a cure, and the second towards ensuring accessibility for those people in need of the treatment. Although there is still much to discover, we got the science right some time ago. The first gene replacement therapy – Gendicine (Shenzhen SiBiono GeneTech) – was approved in China in 2003 and has been successfully administered to more than 30,000 patients with head and neck squamous cell carcinoma. A single dose of this medication costs $400. Another example of early innovation is Neovasculgen (Russian Human Stem Cells Institute), a non-viral gene therapy developed and approved in Russia in 2012 for the treatment of atherosclerotic peripheral arterial disease. It costs less than $50 and its efficacy has been proven in a post-marketing surveillance study. Similar but more recently developed therapeutics bear a much higher cost. For example, Novartis ’ Zolgensma (onasemnogene abeparvovec), released in the US for the treatment of spinal muscular atrophy, costs $2.1 million per patient. Despite Gendicine and Zolgensma both being AAV-based therapeutics, Zolgensma is 5,000 times higher than Gendicine. Pricing curative treatments – sky high vs. rock bottomDan Ollendorf, Director of Value Measurement and Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEV...
Nuclear medicine specialists from Wuhan, China, the epicenter of the COVID-19...Read more on AuntMinnie.comRelated Reading: Small acts of self-care can manage COVID-19 stress RSNA proposes standardized CT reporting for COVID-19 Lung ultrasound identifies patients with COVID-19 Radiology has key role to play in the midst of COVID-19 Radiology experts list COVID-19 best practices
Publication date: Available online 5 March 2020Source: Joint Bone SpineAuthor(s): Alix Frain de La Gaulayrie, Benoît Gobron, Béatrice Bouvard
In late February, Holiday Tours of Randleman celebrated taking delivery of its 100th and 101st bus built by Canadian bus builder Prevost. Officials from both companies were all smiles as they posed beside a bus with an award commemorating the occasion. This week, the 42-year-old family business temporarily closed its doors, furloughing its entire staff and all its drivers in the midst of the economic upheaval caused by coronavirus. Following Gov. Roy Cooper’s stay-at-home orders, Holiday Tours,…
Publication date: June 2020Source: Journal of Functional Foods, Volume 69Author(s): Gengzhen Huang, Shiqing Li, Yaodan Zhang, Xiaoqing Zhou, Wei Chen
The U.S. death toll from the coronavirus has climbed past 3,500, eclipsing China's official count
The White House is expected to release models showing the future course of the disease, and the C.D.C. is reviewing its guidance on wearing masks as new data suggests many people with no symptoms are infecting others.
The United States aims to build hundreds of temporary hospitals to ease pressure on a healthcare system under siege from the coronavirus pandemic, with the U.S. death toll now topping 3,600 to surpass the total in China, where the outbreak began.
Canada's death toll from the coronavirus outbreak jumped by 35% to 89 in less than a day, officials said on Tuesday, and the major province of Quebec said it was running low on key medical equipment.
U.S. coronavirus-related deaths reached 3,393 on Tuesday, exceeding the total number of deaths reported in China and reaching the third highest in the world behind Italy and Spain, according to a Reuters tally.
Second Sight Medical Products is the latest medtech company to face tough losses as a result of the financial impact of the novel coronavirus (SARS-CoV-2). The Sylmar, CA-based company is laying off 84 of its 108 employees and said it intends to wind-down operations. The firm develops implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals. FDA greenlit the Argus II retinal prosthesis system in 2013. Plans now call for the Second Sight to retain an adviser experienced in winding down operations to guide the board on the next steps. Any wind down activity, if impl...
More News: Academia | Accidents | Canada Health | Cancer & Oncology | Carcinoma | China Health | Economy | Education | Gene Therapy | Genetics | Haemophilia | Health Management | Hemophilia | HNSCC | Learning | Lymphoma | Medical Ethics | New York University | Pharmaceuticals | Politics | Russia Health | Science | Skin Cancer | Spinal Muscular Atrophy | Squamous Cell Carcinoma | Stem Cell Therapy | Stem Cells | Study | Tax | Teaching | Universities & Medical Training | Vitamin A